Literature DB >> 19737450

Blood pressure control in the elderly: can you have too much of a good thing?

David J Hyman1, George E Taffet.   

Abstract

Hypertension (especially systolic hypertension) is very common in older persons. Systolic hypertension occurs because large conduit arteries become stiffer with age. Strong evidence from randomized trials suggests that treating systolic blood pressures initially higher than 160 mm Hg is extremely beneficial, and a recent trial extended this conclusion to healthy persons over 80 years of age. However, the only trial that has directly tested the use of more aggressive treatment goals (< 140 mm Hg) in the elderly did not show benefit in those older than 75. Risks of overtreating hypertension for the elderly include falls and orthostatic hypotension, and the most compromised older persons may be the most likely to experience adverse effects. Our current state of knowledge requires clinical judgment that balances the immediacy of adverse effects versus the potential but unproven benefits of treatment in deciding whether to treat the elderly more aggressively than the goals used in randomized trials.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19737450     DOI: 10.1007/s11906-009-0057-y

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  53 in total

1.  Does wave reflection dominate age-related change in aortic blood pressure across the human life span?

Authors:  Mayooran Namasivayam; Barry J McDonnell; Carmel M McEniery; Michael F O'Rourke
Journal:  Hypertension       Date:  2009-04-20       Impact factor: 10.190

Review 2.  What is the role, if any, for beta-blockers as initial therapy for uncomplicated hypertension?

Authors:  Michala E Pedersen; John R Cockcroft
Journal:  Curr Opin Cardiol       Date:  2009-07       Impact factor: 2.161

3.  Postprandial systolic blood pressure responses of older people in residential care: association with risk of falling.

Authors:  David G Le Couteur; Alex A Fisher; Michael W Davis; Allan J McLean
Journal:  Gerontology       Date:  2003 Jul-Aug       Impact factor: 5.140

Review 4.  Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials.

Authors:  F Turnbull; B Neal; T Ninomiya; C Algert; H Arima; F Barzi; C Bulpitt; J Chalmers; R Fagard; A Gleason; S Heritier; N Li; V Perkovic; M Woodward; S MacMahon
Journal:  BMJ       Date:  2008-05-14

5.  Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group.

Authors:  L Liu; J G Wang; L Gong; G Liu; J A Staessen
Journal:  J Hypertens       Date:  1998-12       Impact factor: 4.844

6.  Prospective study of the effect of blood pressure on renal function in old age: the Leiden 85-Plus Study.

Authors:  Thomas van Bemmel; Karen Woittiez; Gerard J Blauw; Femke van der Sman-de Beer; Friedo W Dekker; Rudi G J Westendorp; Jacobijn Gussekloo
Journal:  J Am Soc Nephrol       Date:  2006-08-16       Impact factor: 10.121

7.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

8.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

9.  Isolated systolic hypertension in the elderly: implications of Systolic Hypertension in the Elderly Program (SHEP) for clinical practice and for the ongoing trials.

Authors:  J Staessen; R Fagard; A Amery
Journal:  J Hum Hypertens       Date:  1991-12       Impact factor: 3.012

Review 10.  Mechanical factors in arterial aging: a clinical perspective.

Authors:  Michael F O'Rourke; Junichiro Hashimoto
Journal:  J Am Coll Cardiol       Date:  2007-06-18       Impact factor: 24.094

View more
  4 in total

1.  Frailty, Neurocognitive Impairment, or Both in Predicting Poor Health Outcomes Among Adults Living With Human Immunodeficiency Virus.

Authors:  Kristine M Erlandson; Jeremiah Perez; Mona Abdo; Kevin Robertson; Ronald J Ellis; Susan L Koletar; Robert Kalayjian; Babafemi Taiwo; Frank J Palella; Katherine Tassiopoulos
Journal:  Clin Infect Dis       Date:  2019-01-01       Impact factor: 9.079

2.  Association Between Blood Pressure Control and Risk of Recurrent Intracerebral Hemorrhage.

Authors:  Alessandro Biffi; Christopher D Anderson; Thomas W K Battey; Alison M Ayres; Steven M Greenberg; Anand Viswanathan; Jonathan Rosand
Journal:  JAMA       Date:  2015-09-01       Impact factor: 56.272

3.  Vascular mineralocorticoid receptor regulates microRNA-155 to promote vasoconstriction and rising blood pressure with aging.

Authors:  Jennifer J DuPont; Amy McCurley; Ana P Davel; Joseph McCarthy; Shawn B Bender; Kwangseok Hong; Yan Yang; Jeung-Ki Yoo; Mark Aronovitz; Wendy E Baur; Demetra D Christou; Michael A Hill; Iris Z Jaffe
Journal:  JCI Insight       Date:  2016-09-08

Review 4.  Smooth muscle cell mineralocorticoid receptors: role in vascular function and contribution to cardiovascular disease.

Authors:  Amy McCurley; Adam McGraw; Dafina Pruthi; Iris Z Jaffe
Journal:  Pflugers Arch       Date:  2013-05-01       Impact factor: 3.657

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.